209 related articles for article (PubMed ID: 31579522)
21. Pros and cons of current brain tumor imaging.
Ellingson BM; Wen PY; van den Bent MJ; Cloughesy TF
Neuro Oncol; 2014 Oct; 16 Suppl 7(Suppl 7):vii2-11. PubMed ID: 25313235
[TBL] [Abstract][Full Text] [Related]
22. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
Gandhi L; Ou SI; Shaw AT; Barlesi F; Dingemans AC; Kim DW; Camidge DR; Hughes BGM; Yang JC; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S
Eur J Cancer; 2017 Sep; 82():27-33. PubMed ID: 28646771
[TBL] [Abstract][Full Text] [Related]
24. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.
van den Bent MJ; Wefel JS; Schiff D; Taphoorn MJ; Jaeckle K; Junck L; Armstrong T; Choucair A; Waldman AD; Gorlia T; Chamberlain M; Baumert BG; Vogelbaum MA; Macdonald DR; Reardon DA; Wen PY; Chang SM; Jacobs AH
Lancet Oncol; 2011 Jun; 12(6):583-93. PubMed ID: 21474379
[TBL] [Abstract][Full Text] [Related]
25. Introduction of a standardized multimodality image protocol for navigation-guided surgery of suspected low-grade gliomas.
Mert A; Kiesel B; Wöhrer A; Martínez-Moreno M; Minchev G; Furtner J; Knosp E; Wolfsberger S; Widhalm G
Neurosurg Focus; 2015 Jan; 38(1):E4. PubMed ID: 25552284
[TBL] [Abstract][Full Text] [Related]
26. Assessment of neurological function using the National Institute of Health Stroke Scale in patients with gliomas.
Zeitlberger AM; Flynn MC; Hollenstein M; Hundsberger T
Neurooncol Pract; 2021 Dec; 8(6):699-705. PubMed ID: 34777839
[TBL] [Abstract][Full Text] [Related]
27. Advanced MRI Techniques in the Monitoring of Treatment of Gliomas.
Hyare H; Thust S; Rees J
Curr Treat Options Neurol; 2017 Mar; 19(3):11. PubMed ID: 28349351
[TBL] [Abstract][Full Text] [Related]
28. Response assessment criteria for brain metastases: proposal from the RANO group.
Lin NU; Lee EQ; Aoyama H; Barani IJ; Barboriak DP; Baumert BG; Bendszus M; Brown PD; Camidge DR; Chang SM; Dancey J; de Vries EG; Gaspar LE; Harris GJ; Hodi FS; Kalkanis SN; Linskey ME; Macdonald DR; Margolin K; Mehta MP; Schiff D; Soffietti R; Suh JH; van den Bent MJ; Vogelbaum MA; Wen PY;
Lancet Oncol; 2015 Jun; 16(6):e270-8. PubMed ID: 26065612
[TBL] [Abstract][Full Text] [Related]
29. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.
Nayak L; DeAngelis LM; Brandes AA; Peereboom DM; Galanis E; Lin NU; Soffietti R; Macdonald DR; Chamberlain M; Perry J; Jaeckle K; Mehta M; Stupp R; Muzikansky A; Pentsova E; Cloughesy T; Iwamoto FM; Tonn JC; Vogelbaum MA; Wen PY; van den Bent MJ; Reardon DA
Neuro Oncol; 2017 May; 19(5):625-635. PubMed ID: 28453751
[TBL] [Abstract][Full Text] [Related]
30. Radiology reporting of low-grade glioma growth underestimates tumor expansion.
Gui C; Lau JC; Kosteniuk SE; Lee DH; Megyesi JF
Acta Neurochir (Wien); 2019 Mar; 161(3):569-576. PubMed ID: 30756242
[TBL] [Abstract][Full Text] [Related]
31. Fractionated stereotactic radiotherapy plus bevacizumab after response to bevacizumab plus irinotecan as a rescue treatment for high-grade gliomas.
Conde-Moreno AJ; García-Gómez R; Albert-Antequera M; Almendros-Blanco P; De Las Peñas-Bataller R; González-Vidal V; López-Torrecilla JL; Ferrer-Albiach C
Rep Pract Oncol Radiother; 2015; 20(3):231-8. PubMed ID: 25949228
[TBL] [Abstract][Full Text] [Related]
32. Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials.
Ellingson BM; Brown MS; Boxerman JL; Gerstner ER; Kaufmann TJ; Cole PE; Bacha JA; Leung D; Barone A; Colman H; van den Bent MJ; Wen PY; Alfred Yung WK; Cloughesy TF; Goldin JG
Neuro Oncol; 2021 Feb; 23(2):189-198. PubMed ID: 33130879
[TBL] [Abstract][Full Text] [Related]
33. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
Huang RY; Rahman R; Ballman KV; Felten SJ; Anderson SK; Ellingson BM; Nayak L; Lee EQ; Abrey LE; Galanis E; Reardon DA; Pope WB; Cloughesy TF; Wen PY
Clin Cancer Res; 2016 Feb; 22(3):575-81. PubMed ID: 26490307
[TBL] [Abstract][Full Text] [Related]
34. RANO 2.0: The revised Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade glial tumors in adults designed for the future.
Wen PY; van den Bent M; Vogelbaum MA; Chang SM
Neuro Oncol; 2024 Jan; 26(1):2-4. PubMed ID: 37774741
[No Abstract] [Full Text] [Related]
35. Incidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis.
Abbasi AW; Westerlaan HE; Holtman GA; Aden KM; van Laar PJ; van der Hoorn A
Clin Neuroradiol; 2018 Sep; 28(3):401-411. PubMed ID: 28466127
[TBL] [Abstract][Full Text] [Related]
36. Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients.
Rossmeisl JH; Garcia PA; Daniel GB; Bourland JD; Debinski W; Dervisis N; Klahn S
Vet Radiol Ultrasound; 2014; 55(2):115-32. PubMed ID: 24219161
[TBL] [Abstract][Full Text] [Related]
37. Current concepts in brain tumor imaging.
Norden AD; Pope WB; Chang SM
Am Soc Clin Oncol Educ Book; 2012; ():119-24. PubMed ID: 24451720
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of RANO Criteria for the Assessment of Tumor Progression for Lower-Grade Gliomas.
Raman F; Mullen A; Byrd M; Bae S; Kim J; Sotoudeh H; Morón FE; Fathallah-Shaykh HM
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444384
[TBL] [Abstract][Full Text] [Related]
39. MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives.
Aquino D; Gioppo A; Finocchiaro G; Bruzzone MG; Cuccarini V
J Immunol Res; 2017; 2017():5813951. PubMed ID: 28512646
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
